Structured abstract Background Real-world data for advanced/metastatic non-small cell lung
cancer (NSCLC) with mutations in human epidermal growth factor 2 (HER2) are scarce. We …

Background HER2 mutations occur in∼ 3% of NSCLC; there are no HER2-targeted
therapies approved for pts with NSCLC, representing a high unmet need. DESTINY-Lung01 …

Simple Summary By coupling the potency of cytotoxic chemotherapy with the selectivity of
targeted therapy, antibody–drug conjugates represent a unique and rapidly growing class of …

HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …

Simple Summary The introduction of trastuzumab deruxtecan is significantly changing the
therapeutic landscape of advanced HER2-mutated non-small cell lung cancer (NSCLC) …

Background In the primary analysis of DESTINY-Lung01 (NCT03505710; data cutoff May 3,
2021), T-DXd (a HER2-targeting antibody–drug conjugate) in pts with previously treated …

Purpose This study was conducted to investigate the clinical characteristics of patients with
advanced non–small cell lung cancer (NSCLC) harboring human epidermal growth factor …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Oncogenic mutations and amplifications in the erythroblastic oncogene B (ERBB2), or
human epidermal growth factor receptor 2 (HER2), have emerged as distinct oncogenic …

Methods Patients with HER2-overexpressing metastatic NSCLC were treated with T-DXd 6.4
mg/kg every 3 weeks. The primary endpoint was ORR (CR+ PR) by ICR. Additional …